200 related articles for article (PubMed ID: 24859795)
1. Validation of a bladder symptom screening tool in women with incontinence due to overactive bladder.
Cardozo L; Staskin D; Currie B; Wiklund I; Globe D; Signori M; Dmochowski R; MacDiarmid S; Nitti VW; Noblett K
Int Urogynecol J; 2014 Dec; 25(12):1655-63. PubMed ID: 24859795
[TBL] [Abstract][Full Text] [Related]
2. The validation of the Dutch OAB-q SF: An overactive bladder symptom bother and health-related quality of life short-form questionnaire.
Groenendijk IM; Scheepe JR; Noordhoff TC; Blok BFM
Neurourol Urodyn; 2019 Aug; 38(6):1775-1782. PubMed ID: 31215693
[TBL] [Abstract][Full Text] [Related]
3. Validation of the Turkish version of the eight-item actionable bladder symptom screening tool in multiple sclerosis.
Polat Dunya C; Tulek Z; Vızvız GY; Gündüz T; Panicker JN; Kürtüncü M; Eraksoy M
Neurourol Urodyn; 2020 Jan; 39(1):243-252. PubMed ID: 31588627
[TBL] [Abstract][Full Text] [Related]
4. Psychometric evaluation of the Overactive Bladder Questionnaire (OAB-q) for measuring quality of life and clinical implications in Greek patients with overactive bladder.
Kontogiannis S; Athanasopoulos A; Tsagkarakis M; Kontodimopoulos N
Int Urogynecol J; 2022 Nov; 33(11):3035-3043. PubMed ID: 34626200
[TBL] [Abstract][Full Text] [Related]
5. Quality of life in patients with overactive bladder: validation and psychometric properties of the Spanish Overactive Bladder Questionnaire-short Form.
Arlandis S; Ruiz MA; Errando C; Villacampa F; Arumí D; Lizarraga I; Rejas J
Clin Drug Investig; 2012 Aug; 32(8):523-32. PubMed ID: 22741748
[TBL] [Abstract][Full Text] [Related]
6. Development of a short form and scoring algorithm from the validated actionable bladder symptom screening tool.
Bates D; Burks J; Globe D; Signori M; Hudgens S; Denys P; Macdiarmid S; Nitti V; Odderson I; Ross AP; Chancellor M
BMC Neurol; 2013 Jul; 13():78. PubMed ID: 23837535
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of vibegron, a novel β3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study.
Yoshida M; Takeda M; Gotoh M; Yokoyama O; Kakizaki H; Takahashi S; Masumori N; Nagai S; Minemura K
BJU Int; 2020 May; 125(5):709-717. PubMed ID: 31991511
[TBL] [Abstract][Full Text] [Related]
8. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
[TBL] [Abstract][Full Text] [Related]
9. Reliability and validity of the Overactive Bladder Symptom Score in Spanish (OABSS-S).
Weinberg AC; Brandeis GH; Bruyere J; Tsui JF; Weiss JP; Rutman MP; Blaivas JG
Neurourol Urodyn; 2012 Jun; 31(5):664-8. PubMed ID: 22488591
[TBL] [Abstract][Full Text] [Related]
10. Validation of overactive bladder questionnaire (1-week recall version) in medically complex elderly patients with overactive bladder.
Barsdorf AI; Carlsson M; Bushmakin AG; Quinn S; Cappelleri JC; Pleil A
Int Urogynecol J; 2017 Dec; 28(12):1857-1863. PubMed ID: 28378111
[TBL] [Abstract][Full Text] [Related]
11. Reliability of the Polish version of the Overactive Bladder Symptom Score (OABSS) questionnaire : Correlation of the OABSS with urodynamic study and the UDI-6 and IIQ-7 questionnaires.
Wróbel A; Skorupska K; Rechberger E; Woźniak A; Miotla P; Kubik-Komar A; Skorupski P; Rechberger T
Int Urogynecol J; 2019 Dec; 30(12):2135-2139. PubMed ID: 31396639
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of the actionable bladder symptom screening tool for multiple sclerosis patients.
Burks J; Chancellor M; Bates D; Denys P; Macdiarmid S; Nitti V; Globe D; Signori M; Hudgens S; Odderson I; Panicker J; Ross AP
Int J MS Care; 2013; 15(4):182-92. PubMed ID: 24453782
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive evaluation of bladder and urethral dysfunction symptoms: development and psychometric validation of the Urinary Symptom Profile (USP) questionnaire.
Haab F; Richard F; Amarenco G; Coloby P; Arnould B; Benmedjahed K; Guillemin I; Grise P
Urology; 2008 Apr; 71(4):646-56. PubMed ID: 18313122
[TBL] [Abstract][Full Text] [Related]
14. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
[TBL] [Abstract][Full Text] [Related]
15. Predicting self-perceived antimuscarinic therapy effectiveness on overactive bladder symptoms using the Overactive Bladder 8-Question Awareness Tool.
Villacampa F; Ruiz MA; Errando C; Arlandis S; Arumí D; Lizarraga I; Rejas J
Int Urogynecol J; 2013 Apr; 24(4):573-81. PubMed ID: 23111865
[TBL] [Abstract][Full Text] [Related]
16. Symptomatic overlap in overactive bladder and interstitial cystitis/bladder pain syndrome: development of a new algorithm.
Ackerman AL; Lai HH; Parameshwar PS; Eilber KS; Anger JT
BJU Int; 2019 Apr; 123(4):682-693. PubMed ID: 30253040
[TBL] [Abstract][Full Text] [Related]
17. Sleep Disturbance and Fatigue Are Associated With More Severe Urinary Incontinence and Overactive Bladder Symptoms.
Ge TJ; Vetter J; Lai HH
Urology; 2017 Nov; 109():67-73. PubMed ID: 28826875
[TBL] [Abstract][Full Text] [Related]
18. Barriers experienced by patients with multiple sclerosis in seeking care for lower urinary tract symptoms.
Brucker BM; Nitti VW; Kalra S; Herbert J; Sadiq A; Utomo P; Aponte MM
Neurourol Urodyn; 2017 Apr; 36(4):1208-1213. PubMed ID: 27548624
[TBL] [Abstract][Full Text] [Related]
19. Intravesical electrical stimulation treatment for overactive bladder: An observational study.
Yune JJ; Shen JK; Pierce MA; Hardesty JS; Kim J; Siddighi S
Investig Clin Urol; 2018 Jul; 59(4):246-251. PubMed ID: 29984339
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
